Tadliq is owned by Cmp Dev Llc.
Tadliq contains Tadalafil.
Tadliq has a total of 1 drug patent out of which 0 drug patents have expired.
Tadliq was authorised for market use on 17 June, 2022.
Tadliq is available in suspension;oral dosage forms.
Tadliq can be used as tadliq is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability.
The generics of Tadliq are possible to be released after 24 December, 2038.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US11382917||CMP DEV LLC||Liquid oral formulations for tadalafil|| |
(15 years from now)
Drugs and Companies using TADALAFIL ingredient
Market Authorisation Date: 17 June, 2022
Treatment: Tadliq is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic